Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
1.300
-0.060 (-4.41%)
Jun 20, 2025, 4:00 PM - Market closed
Quince Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Quince Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $8, which forecasts a 515.38% increase in the stock price over the next year. The lowest target is $4 and the highest is $11.
Price Target: $8 (+515.38%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Quince Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +207.69% | Jun 13, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $4 | Strong Buy | Maintains | $4 | +207.69% | Jun 4, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 → $4 | Strong Buy | Maintains | $12 → $4 | +207.69% | Mar 25, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +669.23% | Mar 24, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +823.08% | Feb 5, 2025 |
Financial Forecast
Revenue This Year
n/a
from 215.55M
Revenue Next Year
n/a
EPS This Year
-0.99
from -1.31
EPS Next Year
-0.69
from -0.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 53.7M | ||
| Avg | n/a | n/a | 30.0M | ||
| Low | n/a | n/a | 17.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.86 | -0.12 | -0.03 | ||
| Avg | -0.99 | -0.69 | -0.55 | ||
| Low | -1.05 | -0.89 | -0.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.